Navigation Links
MRSA vaccine shows promise in mouse study

By combining the four bacterial surface proteins that generate the strongest immune response in mice, researchers at the University of Chicago have created a vaccine that significantly protects immunized animals from multiple disease-causing, drug-resistant strains of Staphylococcus aureus, the most common cause of hospital-acquired infections and a rapidly spreading source of community-associated illness.

The vaccine protected mice against potentially lethal infections with five virulent S. aureus strains, the researchers report in the Nov. 7, 2006, issue of the Proceedings of the National Academy of Sciences, available early online. These strains include USA100, a common cause of hospital-acquired infections, and USA400, a virulent community-associated strain that carries lung-damaging toxins. All five strains were resistant to most of the drugs used to treat S. aureus infections.

"This microbe's ability to acquire the tools it needs to protect itself from the drugs we use to treat it is legendary," said study director Olaf Schneewind, M.D., Ph.D., professor and chairman of microbiology at the University of Chicago, "which is why a vaccine has become such a high priority. One by one, this organism has learned how to evade nearly all of our current antibiotics. So, generating protective immunity against invasive S. aureus has become an important goal."

Previous vaccine attempts using killed or live attenuated bacteria, or selected bacterial subunits, produced, at best, only partial immunity. "For S. aureus vaccines to succeed," said Schneewind, "we need to stimulate an immune response that can recognize the specific cell-surface proteins responsible for virulence and can recognize them from multiple strains."

The researchers turned to a newer technique, known as "reverse vaccinology," recently used to develop candidate vaccines against group A and group B streptococci and group B meningococci. Access to the S. aureus genome
'"/>

Source:University of Chicago Medical Center


Page: 1 2 3

Related biology news :

1. Research advances quest for HIV-1 vaccine
2. A much-needed shot in the arm for HIV vaccine development
3. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
4. Gene vaccine for Alzheimers disease shows promising results
5. Influenza vaccine uses insect cells to speed development
6. Norovirus, AIDS vaccine and Hepatitis Virus
7. HIV vaccine trial breaks ground for future research
8. Live vaccines more effective against horse herpes virus
9. NIAID begins clinical trial of West Nile virus vaccine
10. Designing vaccines by computer
11. Wake Forest scientists find new combination vaccine effective against plague
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: MRSA vaccine shows promise mouse study

(Date:7/8/2015)... N.J. and NEW YORK , July 8, ... Guidepoint today announced BD & Guidepoint Mentor, ... with free access to Guidepoint,s expert network services. ... are developing cutting-edge technologies to improve healthcare delivery and ... research manager, each start-up entrepreneur will be able to ...
(Date:7/7/2015)... Calif. , July 7, 2015  Based ... market, Frost & Sullivan recognizes Credence ID, LLC ... Entrepreneurial Company of the Year Award. Credence ... to aid in its mission of offering enrollment ... populations globally. As Credence ID was formed by ...
(Date:7/2/2015)... July 2, 2015 Fingerprint Cards has ... FPC1145 and FPC1155 from the distributor World Peace Industrial Group ... distributors in Asia . Deliveries are planned ... will be used by smartphone manufacturers in Asia ... in the communicated revenue guidance of approximately 2,200 MSEK for ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... ability to promote agricultural and conservation successes in the ... scientists, understanding of how plants adapt to local climate. ... study in the Oct. 7, 2011 issue of ... adaptations to local climate. The National Science Foundation ...
... Agrarian Research (IVIA, Spain) have created a machine that ... segments according to their quality and another that helps ... use computer vision to automatically inspect the fruits. ... dark rooms with the help of ultraviolet light that ...
... York Stem Cell Foundation (NYSCF) announced today that a British ... first recipient of The New York Stem Cell Foundation ... annually for extraordinary achievement in translational stem cell research. ... Director of the London Project to Cure Blindness and Professor ...
Cached Biology News:Oranges and mandarins are inspected using artificial vision 2Oranges and mandarins are inspected using artificial vision 3Professor Peter J. Coffey's stem cell therapy for Age-Related Macular Degeneration expected to begin clinical trials in 2012 2Professor Peter J. Coffey's stem cell therapy for Age-Related Macular Degeneration expected to begin clinical trials in 2012 3
(Date:7/31/2015)... 2015 China Cord Blood Corporation (NYSE: CO) ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has filed its Annual Report ... Commission. The filed Form 20-F includes audited financial statements ... Form 20-F can be accessed by visiting the U.S. ...
(Date:7/30/2015)... , July 30, 2015 AACC ... to the 2015 AACC Annual Meeting & Clinical ... from July 26–30. The meeting showcased revolutionary advancements ... the ability of healthcare providers to diagnose patients ... effective medical treatment. As of ...
(Date:7/30/2015)... Dallas, Texas (PRWEB) , ... July 30, 2015 , ... ... professional and in-depth study on the current state of the global Propanol market with ... are Sinopec, CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal ...
(Date:7/30/2015)... KANSAS CITY, Kan. , July 30, 2015 ... PETX ), a pet therapeutics company focused on ... products for companion animals, today announced that its ... results from a dose confirmation study of AT-016, ... to Aratana for the treatment of osteoarthritis pain ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
... 17 , - New ... Short-Term Mortality Compared to Previous Treatments , ... positive final results,from a Phase II trial of its ... acute myeloid leukaemia (AML). In the,trial, elacytarabine showed statistically ...
... , SHANGHAI, June 17 ... ("China-Biotics", "the Company"), a leading Chinese firm,specializing in ... products, today announced it will join the Russell,3000(R) ... its comprehensive set of U.S. and global equity ...
... (Nasdaq: PRXL ) announced today it will be ... Boston. James Winschel, Senior Vice President & Chief Financial ... 10:15 a.m. EDT on Tuesday, June 23, 2009. ... be available through the "Investor Relations - Upcoming Events" ...
Cached Biology Technology:Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 3Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 5Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 6Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 7China-Biotics, Inc. to Join Russell 3000 Index 2China-Biotics, Inc. to Join Russell 3000 Index 3PAREXEL International to Present at the Wachovia Equity Conference 2
Human MFRP MAb (Clone 291218)...
Human RELT/TNFRSF19L MAb (Clone 238104)...
...
... assay kit measures NOS activity by monitoring ... This assay is simple, sensitive, and specific ... with both crude and purified enzyme preparations. ... for 50 total reactions. Radiolabeled arginine and ...
Biology Products: